Total Funding
79
53
Total FundingPost-IPO Debt raised
Growth Score
-11 pts
Heat Score
5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
50070
Geron is a biotechnology company that specializes in developing blood cancer treatments for hematologic malignancies.
- Aleksandra Rizo: Executive Vice President, Chief Medical Officer
- Melissa Kelly Behrs: Executive Vice President, Business Operations and Chief Alliance Officer
About the Company
Geron is a biotechnology company that specializes in developing blood cancer treatments for hematologic malignancies. The company's Imetelstat, an investigational first-in-class telomerase inhibitor, harnesses Nobel Prize-winning science in a treatment that may change the underlying course of these diseases.
Geron was established in 1990 and
is headquartered in Foster City, California.
